Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial
Dose-finding RCT in older adults found 647–1,032 µg/day oral B12 was needed to normalize mild B12 deficiency markers — orders of magnitude above the RDA, supporting high-dose oral as an alternative to injections.
How to read a study like this
The same questions worth asking about any research paper, not just this one. Worth a minute even if you trust the grade.
Supplement effects often depend on baseline status. Vitamin D helps people who are deficient; iron helps people who are anemic. A result in people unlike you may not apply to you.
A study that shows a blood marker moved isn't the same as a study that shows people felt or functioned better. Ask what the outcome means in practice.
'Statistically significant' only means the effect is unlikely to be zero. It doesn't tell you the effect is large enough to notice. Look for effect sizes, not just p-values.
Industry-funded trials are several times more likely to report positive results than independent ones. It's not usually fraud — it's subtle design and reporting choices. Weight accordingly.
Single positive trials are hypotheses. Replication by independent groups is what turns a hypothesis into reliable evidence. If the only positive trial is the one you're reading, wait.
Supplement marketing routinely cites trials that used 5–10× the dose in the product. If the effective dose was 2 g/day and the capsule has 200 mg, expect roughly no effect.
Not medical advice. This breakdown is for educational purposes. Nothing here constitutes an allegation of fraud or misconduct by any researcher or sponsor. Reasonable scientists can grade the same paper differently; we show our rubric and link every claim to the original study.